Navigation Links
OHSU researchers: Surgery, radiation gives early survival advantage in bile duct cancer
Date:10/28/2007

PORTLAND, Ore. Oregon Health & Science University researchers are reporting the discovery of an early survival advantage when a combination of surgery and radiation therapy is used for patients with a rare but deadly bile duct cancer.

Surgery and radiotherapy shows an early response benefit. It shows that the addition of radiation is potentially reasonable for the first-line treatment, said Clifton David Fuller, M.D., Ph.D., principal investigator of the study. Fuller is a research associate in radiation medicine at OHSU, and a resident in the Department of Radiation Oncology and trainee in Human Imaging/Radiobiology, Division of Radiological Sciences, University of Texas Health Science Center at San Antonio.

A poster of the study will be presented Oct. 28 at the 2007 annual American Society of Therapeutic Radiology and Oncology (ASTRO) meeting in Los Angeles.

The specific cancer type studied, locoregional extraheptitc cholangiocarcinoma (EHCC), is an uncommon cancer of the bile ducts between the liver and gall bladder. Patients with this cancer typically experience symptoms at advanced stages, and cure rates are low even with aggressive therapy. Patients with this cancer have extremely poor prognosis, with an average five-year survival rate of 5 to 10 percent. The reported incidence of cholangiocarcinoma is one to two cases per 100,000 people in the U.S.

Because these cases are relatively rare, whether radiation should be added to surgery has remained a matter of debate. Because the numbers have been too small to launch a head-to-head trial, we have sought to determine baseline survival for people with this cancer receiving surgery and radiotherapy using a large data set. This study presents results from the largest population-based data set for patients with this cancer, said Charles Thomas, M.D., co-author of the study, and OHSU chairman of radiation medicine and professor of medicine.

A total of 2,591 cases of cholangiocarcinoma diagnosed from 1973 to 1998 were taken from the Surveillance, Epidemiology and End Results (SEER) program of the National Cancer Institute. Cases were sorted into surgery alone; radiotherapy alone; surgery and radiotherapy; and neither surgery nor radiotherapy.

Researchers found that early survival increased when surgery and radiation were combined. Those receiving both treatments were more likely to survive the first two years after diagnosis, even though the five-year survival remained similar for both groups. The addition of radiation to surgery also was associated with increased median survival.

Were not sure why this early survival benefit disappears. It could be that radiation delays the progression of the disease, and delays disease progression, but we dont know for sure. However, in the absence of clinical trial data, it is reasonable to suggest radiation plus surgery or surgery alone as the prescribed treatment for this cancer, given our observations. Patients selecting treatment should ask their doctors whether radiation should be added to surgery in their particular cases, Fuller said.


'/>"/>

Contact: Christine Decker
deckerch@ohsu.edu
503-494-8231
Oregon Health & Science University
Source:Eurekalert

Related medicine news :

1. UC Researchers: Low-cost malaria cure will not be a distant dream
2. PM Undergoes Wrist Surgery, Returns Home
3. Bypass Surgery, a Better Option than Angioplasty for Severe Heart Patients
4. Surgery, the Best Option for Kids With High Blood Pressure
5. Surgery, Radiation Treatment Double Life Expectancy for Prostate Cancer Patients
6. Bypass Surgery, Drug-eluting Stents Possess Similar Risk and Outcome
7. NHS Oversupplied With Cataract Surgery, Say Doctors
8. Antioxidants protect health tissue in people undergoing radiation therapy.
9. Radiation for Bone Pain
10. Radiation for Bone Pain
11. Gene enchances radiation therapy - A novel approach to fight cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... the introduction of an innovative new design of the shoulder pad. The shoulder ... maximum comfort while controlling your pain while using cold therapy. By utilizing ice and ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information ... we intend to develop to enable prevention of a major side effect of ... loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label ...
(Date:10/12/2017)... D.C. (PRWEB) , ... October 12, 2017 , ... Leading ... their peers in Washington, D.C., for the 49th Congress of the International Society ... ., Vice President of the Center for Cancer and Blood Disorders at ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... (HLA), the nation's first interactive health literacy software tool, and the Cancer Patient ... aspects of cancer patient education, today announce a new strategic alliance. , ...
(Date:10/12/2017)... Washington, D.C. (PRWEB) , ... October 12, 2017 ... ... Company, Cal Dining at the University of California Berkeley, and other leading institutions ... leverages the buying power of institutions to change the way animals are raised ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans ... advance the use of wearable and home sensors for ... disorders. Early Signal Foundation, a nonprofit organization focused on ... will provide an affordable analytical system to record and ... ...
(Date:9/27/2017)... , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading global ... that its MyDario product is expected to appear on The Dr. Oz ... Dr. Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz Show kicked ... The segment features ...
(Date:9/25/2017)... R.I. , Sept. 25, 2017  EpiVax, ... assessment, vaccine design, and immune-engineering today announced the ... on the development of personalized therapeutic cancer vaccines. ... has provided exclusive access to enabling technologies to ... Eng., MBA will lead EpiVax Oncology as Chief ...
Breaking Medicine Technology: